Increased expression of GFAP in TMZ-sensitive (Figure 6I) and TMZ-resistant (Figure 6L) xenograft tumors after TMZ-combined SMP treatment suggests that this drug combination may affect the processes of cell differentiation and reduce the malignancy of human glioma cells. The gene discussed is GFAP; the disease is central nervous system cancer.